Product Description
Mechanisms of Action: ACE Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Austria | Belgium | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Czech | Egypt | Germany | Greece | Hungary | Ireland | Israel | Italy | Korea | Morocco | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Russia | Serbia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Turkey | United Kingdom | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|